Mesoblast annual revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Mesoblast Revenue Growth & History (MESO)
Mesoblast reported $120.3M in revenue for fiscal 2026, an increase of 599.21% from the previous fiscal year.
View full Mesoblast company overviewMesoblast annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | $120.3M | $103.1M | +599.21% |
| 2025 | 2025-06-30 | $17.2M | $11.3M | +191.39% |
| 2024 | 2024-06-30 | $5.9M | −$1.6M | −21.32% |
| 2023 | 2023-06-30 | $7.5M | −$2.7M | −26.54% |
| 2022 | 2022-06-30 | $10.2M | $2.8M | +37.36% |
| 2021 | 2021-06-30 | $7.4M | −$24.7M | −76.88% |
| 2020 | 2020-06-30 | $32.2M | $15.4M | +92.30% |
| 2019 | 2019-06-30 | $16.7M | −$619,000 | −3.57% |
| 2018 | 2018-06-30 | $17.3M | $14.9M | +618.95% |
| 2017 | 2017-06-30 | $2.4M | −$40.1M | −94.33% |
| 2016 | 2016-06-30 | $42.5M | — | — |
Mesoblast quarterly revenue
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q3.21
Q1.22
Q3.22
Q1.23
Q3.23
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q3 2023 | 2023-03-31 | $1.9M | −$72,000 | −3.58% |
| Q1 2023 | 2022-09-30 | $1.5M | −$2.1M | −58.18% |
| Q3 2022 | 2022-03-31 | $2.0M | $96,000 | +5.01% |
| Q1 2022 | 2021-09-30 | $3.6M | $2.3M | +175.40% |
| Q3 2021 | 2021-03-31 | $1.9M | −$10.3M | −84.30% |
| Q1 2021 | 2020-09-30 | $1.3M | −$15.7M | −92.35% |
| Q4 2020 | 2020-06-30 | $701,000 | −$1.3M | −64.34% |
| Q3 2020 | 2020-03-31 | $12.2M | $11.0M | +876.86% |
| Q2 2020 | 2019-12-31 | $2.2M | $336,000 | +17.97% |
| Q1 2020 | 2019-09-30 | $17.0M | $5.4M | +46.50% |
| Q4 2019 | 2019-06-30 | $2.0M | — | — |
| Q3 2019 | 2019-03-31 | $1.2M | $179,000 | +16.73% |
| Q2 2019 | 2018-12-31 | $1.9M | −$11.5M | −86.04% |
| Q1 2019 | 2018-09-30 | $11.6M | — | — |
| Q3 2018 | 2018-03-31 | $1.1M | — | — |
| Q2 2018 | 2017-12-31 | $13.4M | — | — |
Mesoblast revenue growth trends
Over the last five reported fiscal years, revenue grew from $7.4M to $120.3M, a compound annual growth rate of 74.49%. Mesoblast's latest reported quarter, Q3 2023, generated $1.9M in revenue, a decrease of 3.58% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Mesoblast source filings ↗Community posts
Mesoblast gains FDA clearance for a new Ryoncil potency assay
Mesoblast ($MESO) received FDA approval to use a new potency assay for the release and stability testing of newly manufactured commercial Ryoncil batches. The TIBA assay is intended to identify changes in product potency, including those as ...
